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transplantation and immunosuppression differ. Although young transplant recipients are ultimately likely
to be considered for re-transplantation. One has to distinguish between myopathy and complex congenital
heart disease (CHD). The differences in anatomy and physiology make the surgical procedure much more
complex and create unique challenges. These recipients need a well-organized and educated team with
pediatric cardiologists and intensivists, including a high skilled surgeon, which is dedicated to pHTx.
Therefore, these types of transplants are best concentrated in specialized centers to achieve promising
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Introduction
Treatment of patients suffering from end-stage heart 
failure (HF) leaves surgeons with limited options. The 
failing heart may be treated for a short period of time 
by medications, but in the absence of other correctable 
diseases without either replacing the heart [heart 
transplantation (HTx)] or mechanical circulatory support 
(MCS), the destiny of the patient will take a fatal run. HTx 
is considered to be the “golden standard” for patients, 
both adults and children, suffering from end stage HF. 
Just three days after the world’s first human HTx, Adrian 
Kantrowitz performed this pioneering procedure on 
a 19-day-old neonate, recording the world’s second 
HTx. Unfortunately the infant died only hours after the 
operation (1). It would take another 16 years before a 
neonatal HTx was performed again (2). The development 
of cyclosporine-based immunosuppression regimens years 
later stimulated an increased application of HTx (3). In 
2011, 565 HTx in patients below 18 years were reported 
to the registry of the International Society for Heart and 
Lung Transplantation (ISHLT); about 25% of the patients 
were infant recipients (4). 
Special features in pediatric heart 
transplantation (pHTx)
Hospitalization among children suffering from HF due 
to congenital heart disease (CHD) is increasing (5) and 
pHTx may remain the only option for some of these 
young patients. PHTx accounts for approximately 14% 
of the total HTx (4). Today more than 11,000 pHTx 
have been reported to the registry of the ISHLT. We may 
examine the evolving management and outcome of this 
therapy. Compared to the adult population, there are some 
crucial differences worth mentioning. This article tries to 
highlight some of these differences; starting with the initial 
diagnosis leading to HF, donor selection, including ABO 
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incompatible (ABOi) transplantation, waitlist management 
and some brief comments concerning surgical techniques.
The pediatric heart transplant recipient
Diagnoses leading to pHTx are age-specific and have 
also changed during the past decades. The devastating 
constellation of left heart anomalies summarized under 
the name of hypoplastic left heart syndrome (HLHS) was 
one of the reasons to introduce infant pHTx. In the last 
two decades, organ shortage especially for neonates made 
it clear that primary HTx was an impractical therapy for 
the large number of infants with HLHS (2). Attempts 
towards reconstructive, palliative surgery in this patient 
population led to staged surgery [Norwood procedure (6)] 
and became the primary treatment option. This explains 
that the percentage of recipients listed for pHTx with the 
diagnosis of CHD has decreased from 81% in the 1990s 
down to 54% in 2013 (4). Still, CHD remains the most 
common indication for pHTx in the infant age group (4). 
Out of the patients listed with CHD 60, 70% have single-
ventricle physiologies. In 11 to 17 year olds, the percentage 
of recipients with the diagnosis of CHD decreases to 
23% whereas the percentage of myopathy increases to 
65% (see Table 1). The entity of cardiomyopathy (CMP) 
may be distributed in: 75% dilated, 12% restrictive, 8% 
mycoarditis and 5% hypertrophic (7). Population based 
studies show an incidence of CMP between 0.87 to 1.3 per 
100,000 children with a median age at diagnosis of 1 year. 
The physicians taking care of the children with moderate to 
severe HF should also monitor growth of the child; besides 
severe HF with ventricular dysfunction, moderate HF with 
ventricular dysfunction with significant growth retardation 
should also be evaluated for pHTx. Notwithstanding the 
great advances made over the past several years, HTx 
remains a time-limited therapy. Analyses have reported an 
estimated half-life of 13.9 years for children after HTx (4). 
Especially the pediatric population is ultimately likely to be 
considered for re-transplantation. Nine per cent of children 
between 11 to 17 years are listed for re-transplantation (4). 
It has to be mentioned that there seems to be geographical 
differences as re-transplantation is most common in North 
America at 6% compared to only 2% in the rest of the 
world. Most of the re-transplantations (72%) will be made 
beyond three years after the primary HTx. Children with 
a previous transplant are likely to be sensitized, which may 
explain in parts that re-transplantation remains a risk factor 
for mortality up to 15 years post-transplant (4). Likewise, 
survival after re-transplantation is reduced compared with 
CMP but it is not significantly different from patients with 
CHD (4).
Patient selection remains a crucial factor for the outcome. 
Basic and specific examinations have to be conducted to 
exclude contraindications prior to listing (see Table 2). 
Neuromuscular disorders including Becker and Duchenne 
disease are frequently associated with the development 
of CMP and should be searched for. The pulmonary 
vascular resistance must be measured prior to listing 
because a fixed pulmonary hypertension (transpulmonary 
gradient >15 mmHg, pulmonary artery systolic pressure 
>55 mmHg and pulmonary vascular resistance >6 μm2) 
is contraindicating pHTx. Other contraindications, such 
as severe extra-cardiac malformations (chromosomal and 
genetic syndromes with poor quality of life prognosis), 
ongoing malignancy, have to be searched for (see Table 2). In 
complex congenital anatomy beside cardiac catheterization, 
cardiovascular imaging including computer tomography 
scan or magnet resonance imaging will be required. As 
a result of previous cardiac surgeries, pediatric heart 
transplant recipients are at a particular risk of sensitization 
affecting the postoperative immunosuppressive (IS) regime 
and the outcome.
Finally, a strong reliable social support system is 
essential for long-term success. Family members must often 
restructure their daily routines to care for their children. 
Therefore, the child along with his/her family must 
undergo a complete psychosocial evaluation (8). 
Awaiting pHTx
Many candidates are stable enough to be managed as 
outpatients. Optimal medical treatment, including diuretics, 
angiotensin-converting enzyme inhibitors and β-blockers, 
Table 1 Indications for transplantation in children according 
to the registry of the International Society for Heart and Lung 
Transplantation
Age  
(year)
CHD (%) Myopathy (%) Re-Tx (%) Others (%)
<1 54 41 0.4 4
1-5 39 56 2 3
6-10 32 59 7 2
11-17 65 65 9 3
CHD, congenital heart disease; Re-Tx, cardiac re-transplantation.
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attempts to preserve end-organ function. If this fails, in-
hospital treatment with intravenous inotropic support will 
be necessary. If despite inotropic support critical peripheral 
perfusion (i.e., metabolic acidosis; cardiac index <2.0 L/m2/min, 
mixed venous oxygen saturation <40%) with early signs of 
renal, hepatic or multi-organ failure occur, MCS should be 
considered. 
The lack of suitable donor organ is displayed by the 
amount of patients listed for HTx in Eurotransplant 
(ET) countries which has doubled between 2003 and 
2011, whereas the number of HTx stayed the same (9). In 
Switzerland the median waiting time for a donor heart has 
increased over the last five years from 104 to 276 days in 
2013. Simultaneously there is an almost three fold increase 
of patients on the waitlist (Annual Swisstransplant report 
2013). Especially children are at an increased risk of death 
on the waiting list (10). The limited numbers of available 
pediatric donor heart organs led to an increased mean 
waiting time in ET of 322 days for patients under five 
years of age (ET Annual report, 2012). In Switzerland the 
number of paediatric heart transplant candidates between 
2009 and 2013 was more than four times bigger than 
during the 2004-2008 period (see article Weiss et al. in this 
issue). To prevent death while waiting, MCS support was 
introduced very early. 
Ventricular assist devices (VADs) in children
VADs as bridge to transplantation (BTT) have become 
widely accepted in adult practice with excellent results 
(see article Pozzi et al. in this issue). There is a large 
variety of adult sized VADs but only a small number are 
available for children with a body surface area (BSA) of less 
than 1.2 m2 or weight less than 20 kg. Most centres have 
experience with extracorporeal membrane oxygenation 
(ECMO) as BTT; nevertheless ECMO application is 
limited to short-term support. Therefore VADs have also 
evolved over the past few years with promising outcomein 
the pediatric population (11-13). Crucial for successful 
BTT remain patient selection and timing. In patients 
with critical peripheral perfusion and a cardiac index 
<2.0 L/m2/min, despite inotropic support, MCS should 
be considered. There are only a few contraindications for 
MCS like malignant neoplastic diseases with a very limited 
life expectancy, advanced multi-organ failure, irreversible 
pulmonary failure and severe extra-cardiac malformations 
Table 2 Contraindications for pediatric heart transplantation 
Absolute contraindications Remarks
Active infection
Ongoing malignancy
Medical noncompliance
Drug abuse
Non-reactive pulmonary vascular resistance Left ventricular assist device implantation
Presence of non-cardiac conditions that shortens life expectancy
Recent or unresolved pulmonary infarction
Psychiatric illness considered likely to interfere significantly with compliance
Systemic disease likely to limit  post-transplant survival
Active peptic ulcer disease with recent gastrointestinal bleeding Medical treatment and surveillance
Relative contraindications
Renal insufficiency* Combined heart and kidney transplant
Ventricular assist device implantation 
History of malignancy Depending on time after diagnosis
Hepatic dysfunction* Liver biopsy to exclude liver cirrhosis
Combined heart and liver transplant
Symptomatic peripheral or cerebrovascular disease.
Obesity (body mass index >32)
*, not explained by the underlying heart failure and deemed irreversible.
555Journal of Thoracic Disease, Vol 7, No 3 March 2015
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2015;7(3):552-559www.jthoracdis.com
such as chromosomal and genetic syndromes with poor 
quality of life prognosis (which would also exclude them 
from cardiac transplantation). There is evidence that 
similar to adults, making decision in favor of earlier VAD 
implantation results in better outcome, especially in 
children under one year of age (14). In our own experience, 
MCS was initiated in 65% of recipients on the waitlist (15).
Expanding organ donation criteria
On the other side, the crucial shortage of donors has led 
to various approaches to improve organ availability (16) 
and graft utilization. To expand the donor pool, liberated 
organ donation criteria such as increasing age or other 
co-morbidities were adapted. Today, almost every fourth 
heart organ donor in Europe (23.2%) is 50 years of age 
or older (17). The proportion of adult donors allocated to 
pediatric recipients is 18% in the US but is as high as 43% 
in Europe and 48% in the rest of the world (4). Lately, 
the Vienna group of Eskandary et al. found no interaction 
between donor and recipient age negatively affecting 
mortality and cardiac allograft vasculopathy (CAV) (18). 
Others showed that older recipients, who received an older 
donor heart, had progressively worse survival rate (19). 
In the 2012 ISHLT registry report, only the donor age 
but not the recipient age was a risk factor for developing 
CAV (20). Concerning the use of donor hearts from resuscitated 
organ donors seems there are some hopeful publications. 
Using the UNOS database, Quader et al. (21) assessed the 
effect of donor cardiopulmonary resuscitation (CPR) on 
outcomes after cardiac transplant. The authors did not 
observe a negative effect of CPR on recipient survival 
at 30 days, 1 or 5 years (22). Similarly at the 2014 annual 
meeting of the ISHLT Khan et al. showed that donor heart 
organs from cardiopulmonary resuscitated donors do not 
decrease cardiac graft survival (abstract #97) (23). 
The use of anencephalic neonates as organ donors has 
been discussed. Official statements from the Canadian 
Paediatric Society and the American Academy of Pediatrics 
affirmed that anencephalic infants are not appropriate organ 
donors. In an update of the canadian statement in 2005 
it is recommended: Organ donation from anencephalic 
infants should not be undertaken due to the serious 
difficulties surrounding the establishment of brain death 
in these infants and the lack of evidence to date supporting 
successful organ transplantation. There should be no 
alteration or modification of standard infant brain death 
criteria to include infants with anencephaly (24).
An innovative strategy for the infant age group that 
proved to be successful was the introduction of ABOi 
transplantation (25). 
ABO incompatible (ABOi) transplants
Infant heart transplant recipients are at a greater risk of death 
before transplantation than older children. The main reason 
is the search for an appropriately sized organ donor. This 
compelling motivation challenged previously unquestioned 
mandates such as ABO compatible transplantation. 
Introduction of intentional ABOi HTx was based on the 
immaturity of the immune system in this age group (26). 
Analysis has demonstrated persistent deficiency of antibodies 
toward the donor blood group in infants as well as absence 
of B-cells with specific receptors for donor blood group 
antigens. The stage of immunologic maturation with 
regard to isoagglutinin production is the main parameter to 
judge suitability for ABOi transplant. In the UK an ABOi 
transplant was performed in a 2-year-old child still without 
isoagglutinins (27). Preoperative anti-ABO titers of 1:4 
seem to be safe. A European single center study using 
the Toronto protocol confirmed the good results (28). 
Autotransfusion devices were used perioperatively to recover 
autologous red cells proved to be safe to remove all circulating 
isohemagglutinins during the washing procedure (28). 
If circulating antibodies have accumulated plasma exchange 
has to be done directly from cardiopulmonary bypass during 
HTx; before opening the aortic cross clamp all circulating 
anti-donor antibodies must have been removed (8). 
Attention to ensure appropriate blood group products is 
essential; Plasma and platelets must be from donor blood 
type whereas packed erythrocyte transfusions can be of the 
recipient. 
ABOi pHTx has led to a marked reduction in waitlist 
mortality in Canada and shorter time periods on the waitlist 
in the US (29). Recently, an international multi-center 
trial reported actuarial graft survival of 100% at one year, 
96% at five years and 69% at 10 years post-transplant. The 
oldest recipient in this cohort at the time of transplant was 
7.5 years (29). 
Long-term outcome
Patient selection, waitlist management, quality of the organ 
donor heart, the surgical procedure itself and post-operative 
treatment will affect successful long-term outcome. Despite 
a higher mortality of one year, the youngest recipients 
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experience the longest survival of all age groups with 
19.7 years for infants, 16.8 years for recipients aged one to 
five, and 14.5 years for recipients between ages of six and 
10 years (4). Causes of death depend on the time interval 
after HTx. In the early period, outcome is closely linked to 
operative mortality as well as acute graft function. Allograft 
rejection remains an important cause of mortality and 
morbidity. Medical prophylaxis and treatment (IS drugs) is 
necessary. In contrast to the adult population, most (71%) 
pediatric transplant recipients receive induction therapy; 
either anti-thymocyte globulin or interleukin-2 receptor 
antagonists. Risk analyses showed that children receiving 
polyclonal induction therapy have a better survival than 
those receiving IL2-R antagonists (4). Maintenance 
IS therapy comprises a three drug regime, including a 
calcineurin inhibitor, mycophenolate mofetil or acid and 
prednisolon. Most of the centers try to wean away the 
recipient from cortocosteroids after a certain period of 
time. Weaning of these patients seems to be justified by the 
ongoing discussion on the negative impact of IS drugs on 
somatic growth. So far, reports indicate sufficient growth 
in the children (most present with normal range height and 
weight scores). Still acute rejection remains a serious event, 
accounting for 5% of deaths even 10 years post-transplant. 
The worst outcome concerning rejection has recipients 
with treatable rejection periods within the first year after 
transplantation. Fortunately there is a distinct decrease of 
treated rejection over the last few decades (4). Recipients 
suffering from CHD are at a high immunological risk 
regarding rejection. The proportion of sensitized recipients 
with panel reactive antibody (PRA) is especially high (27%) 
in the pediatric population (4). Circulating anti-donor 
antibodies can result in cellular and humeral rejection; 
they result from previously received blood transfusions, 
post-gravid adolescent girls, surgical implantation of 
cryopreserved tissue valves, conduits, previous transplants, 
VADS/ECMO or even central venouse catheters. A percent 
of PRA greater 10% was shown to have inferior outcome 
compared to non-sensitized patients (8). Besides different 
IS regimes to treat recurrent rejection, extracorporeal 
photopheresis may be another promising option (30). 
Chronic graft failure, known as cardiac artery vasculopathy 
(CAV) is one of the main risk factors for death (26.3% >10 years 
post-transplant). There seems to be a slower progress 
of CAV in infants and young children but when CAV is 
diagnosed, graft survival drops to about 50% after five 
years regardless of recipient age (4). Different risk factors 
for developing CAV have been reported, including donor 
cause of death, donor/recipient age difference, weight ratio, 
gender mismatch, use of no induction therapy compared 
to the use of induction therapy, different use of IS drugs. 
Treatment options are limited and heart re-transplantation 
is often the only option. Re-transplantation itself was found 
to be a risk factor for mortality in multivariate analyses 
(five year survival in children was 58%). Side effects of 
IS treatment, including chronic renal failure, increased 
risk of malignancy or infections determine morbidity (4). 
Although the greatest risk to die from infection is within 
the first year after pHTx infections remain a significant 
source of mortality and morbidity in the long-term (31). 
In the initial time after transplantation bacteria are the 
most common cause of infectious disease which changes to 
virus infections (i.e., CMV, EBV, Herpes simplex, Varicella 
zoster Parvovirus) and opportunistic infections such as 
Aspergillus, Pneumocvystis, Toxoplasma gondii. Contrary 
to older patients pediatric recipients seems to have a special 
high risk of lymphoma (32). While all HTx recipients 
are at an increased risk of malignancy post-transplant 
lymphoproliferative disease (PTLD) still represents the 
most cases in children (4). Besides age other risk factors 
associated with PTLD are increased frequency of rejections 
or use of OKT3 induction. The most important risk factor 
however is the Ebstein-Barr virus (EBV) serologic status. 
A high percentage of children are EBV negative as they 
do not acquire infection until adulthood; nevertheless also 
transplant candidates who contract EBV from the donor 
(even if EBV serology is positive) have an increased risk 
of PTLD.
Despite clinical characteristics (dialysis, ventilation, 
hospitalization) at the time of transplant, diagnosis and age, 
MCS remains a significant risk factor for mortality (4).
Operative techniques
HTx for complex CHD remains a technically challenging 
procedure and needs a well-trained team of surgeons, 
anesthesiologists, nurses, cardiologists and intensivists. 
Even though Ellsworth E. Wareham asserted: “Heart 
surgery is nothing more than a few simple steps, done well”, 
a transplant surgeon for pHTX needs more than just a Plan 
A and B and should be equipped with multiple bail out 
strategies. Donor heart procurement and pHTx, especially 
in complex CHD, need careful planning and a thorough 
understanding of the recipient’s anatomy. Most of the 
recipients have one or sometimes even numerous previous 
open heart surgeries. Establishing cardiopulmonary bypass 
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in recipients with CHD should address residual defects 
that cannot be corrected by implantation of a normal 
heart (systemic and pulmonary venous anomalies, aortic 
arch obstruction or pulmonary branch defects), heterotaxy 
syndrome as well as anomalies of the systemic venous return 
(such as bilateral superior venae cavae) (8). Anomalous 
systemic venous connection has been observed in the 
general population about 0.1-3% and is more common with 
CHD (33,34).
Successful outcome will start with organ selection and 
organ harvesting. Selection of the donor organ has to take 
some aspects in considerations (8). A donor-recipient weight 
ratio of >2.5 and <0.5 adversely effects outcome (35). Likewise 
donor age might play an important role for pediatric 
recipients (36) whereas gender seems to have no significant 
impact on outcome. Finally one has to think about ischemic 
time; depending on the status of the recipient one has to 
wait for longer ischemic time versus longer waiting time 
including the possibility of death on the waitlist. Varying 
from routine donor heart harvesting, additional donor 
tissue additionally including the full length of the venae 
cavaesuperior and the innominate vein as well as the entire 
aortic transverse arch and the branch pulmonary arteries 
should be explanted.
“Univentricular hearts” and “Failing Fontan”
Reconstructive surgery, known as Norwood stage 1 to 3 or 
Fontan procedure, is a successful palliation in patients with 
single-ventricle physiology. Nowadays, HTx is reserved 
for those few newborns who do not seem suitable for the 
ultimate Fontan physiology (2). In neonates with HLHS 
the aortic arch is too small for aortic cannulation for 
cardiopulmonary bypass. In these cases the main pulmonary 
artery and the ductus can be used. Another option may be 
to suture a graft to the innominate artery. If HTx is done 
after the bidirectional cavopulmonary connection (Norwood 
stage II) has failed due to pulmonary resistance and the 
Fontan completion (Norwood stage III) is not possible, 
a takedown of the Glenn ansatomosis and cavo-caval 
transplantation is required.
After the Fontan completion late hemodynamic 
complications like HF, cyanosis and protein-losing 
enteropathy occure patients should be evaluated for HTx. 
Often more than one factor may led to transplantation i.e., 
significant cyanosis limiting exercise capacity and failing 
Fontan physiology (37). Besides marginal liver function, 
coagulopathy, several previouse heart operations the 
distorted anatomy may be a great challenge for the surgical 
team. The post-transplant survival in this patient population 
seems to be good but there are some high-risk factors like 
younger patients age who had not had the Fontan operation 
or who were <6 months from their Fontan procedure and 
ventilator dependent recipients (38). 
Describing the multitude of different techniques to 
address cardiac transplantation in complex CHD would go 
beyond the scope of this article. Besides all the adversities, 
“the real trump card of surgery is the fact that the native 
organ is being removed” (8).
Congenital heart disease (CHD) in adulthood
The population of adult CHD patients is growing over 
the last several years due to improved survival through 
childhood (17). It is estimated that 10-20% of patients 
suffering from complex CHD will require HTx at some 
time of her/his life. They are at a higher risk of mortality 
due to myocardial dysfunction and HF (39). In an analysis 
of the UNOS database, Gelow et al. showed that CHD 
patients are less likely to receive an allograft while listed, are 
less likely to receive VAD therapy and more likely to die on 
the waitlist (40). In contrast, favorable long-term survival 
after HTx has been published for this patient population 
(41-43). These patients pose new challenges to transplant 
therapy.
Conclusions
pHTx has evolved over the years to a well-established, live 
saving procedure with excellent long-term outcome. In 
the next years, adults with CHD, new IS regiments and 
avoidance of long-term morbidity after pHTx will be just 
some of the issues to focus on.
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